SCHEMBL4353757

SCHEMBL4353757

Oc1c(F)cccc1NC(=S)Nc1ccccc1C(F)(F)F

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.60
ALDH1A1 P00352 10/20 0.53
MAPT P10636 4/20 0.53
KDM4E B2RXH2 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
HPGD P15428 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
GAA P10253 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
KDM4C Q9H3R0 1/20 0.49
ALOX12 P18054 3/20 0.48
NPSR1 Q6W5P4 1/20 0.48
LMNA P02545 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4360056 0.85 KMT2A (0.54) KMT2AALDH1A1MAPTKDM4ESMN1; SMN2
SCHEMBL9453927 0.85 ALDH1A1 (0.67) KMT2AALDH1A1MAPTKDM4ESMN1; SMN2
SCHEMBL4346886 0.84 KMT2A (0.63) KMT2AALDH1A1MAPTKDM4ESMN1; SMN2
SCHEMBL4349649 0.82 KMT2A (0.61) KMT2AALDH1A1MAPTKDM4ESMN1; SMN2
SCHEMBL4345927 0.82 KMT2A (0.51) KMT2AALDH1A1MAPTKDM4ESMN1; SMN2
SCHEMBL4347353 0.80 KMT2A (0.58) KMT2AALDH1A1MAPTKDM4ESMN1; SMN2
SCHEMBL4348052 0.79 KMT2A (0.51) KMT2AALDH1A1MAPTSMN1; SMN2CYP1A2
SCHEMBL6230061 0.78 KMT2A (0.67) KMT2AALDH1A1MAPTKDM4ESMN1; SMN2
SCHEMBL4350936 0.77 KMT2A (0.62) KMT2AALDH1A1MAPTKDM4ESMN1; SMN2
SCHEMBL7819531 0.76 KMT2A (0.59) KMT2AALDH1A1MAPTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
CN-100546977-C Suppress the new compound and the application thereof of rotamase JERINI AG (DE) 2009-10-07 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 KMT2A 2096/4885ALDH1A1 2565/4885MAPT 4439/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 KMT2A 1254/4885ALDH1A1 2767/4885MAPT 4184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.